Login

Financial Snapshot

Revenue
TTM
$105.0K
Gross Margin
TTM
1.9%
Net Income
TTM
-$14.21M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
2259.46%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$74.11M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$15.38M

Stock Price

Loading...
Market Cap: $135 Million

About Microbot Medical Inc

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-revenue medical device company developing robotic surgical systems for endovascular procedures. The company generates no product revenue as of fiscal year ended December 31, 2025, and finances operations through equity offerings, potential licensing or collaboration arrangements, grants, and debt financings. Its lead product candidate is the LIBERTY Endovascular Robotic Surgical System, which remains subject to regulatory clearance. Harel Gadot serves as President, Chief Executive Officer, and Chairman, as of March 26, 2026. The company is incorporated in Delaware and has operations with Israeli roots, including prior activity under Microbot Israel. No dividends have been paid, and none are anticipated. The company does not have committed external funding sources and expects continued losses until, if ever, it reaches profitability.

Revenue model
No product revenue is disclosed in the FY2025 10-K. The company funds operations through equity offerings, including potential at-the-market offerings, licensing or collaboration arrangements, grants, and debt financings.
Products and services
Lead product candidate: LIBERTY Endovascular Robotic Surgical System. The product was not commercially approved as of the filing date (March 26, 2026) and is subject to FDA 510(k) clearance.
Customers and end markets
Target end markets include hospitals and medical institutions performing endovascular procedures. Acceptance by the medical community, patients, and third-party payors is identified as a condition for commercial success. No customer revenue is disclosed for FY2025.
Value-chain role
Early-stage medical device developer. Plans to establish commercial manufacturing arrangements with third parties and build out sales, marketing, and distribution capabilities upon regulatory approval.
Geographic exposure
Operations span the United States and Israel. Regulatory pathways referenced include the FDA (United States) and Israel's Ministry of Health. Israeli-manufactured device registration processes are described in the filing.

Source: SEC 10-K, filed 2026-03-26

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Conformis Inc INVACARE HOLDINGS Corp IRIDEX Corp Nemaura Medical Inc. SANUWAVE Health Inc Vivani Medical Inc Scientific Industries Inc Talis Biomedical Corp

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support